Frequency Of Actionable Somatic Alterations With Genomic Profiling: The Columbia University Experience.

e23132Background: Personalized medicine in oncology is increasingly available due to the development of more targeted therapies as well as the decreasing expense and rapid results of next generation sequencing (NGS). At Columbia University Medical Center, patients undergo genomic profiling with a NGS assay called the Columbia Combined Cancer Panel (CCCP). We sought to assess the frequency of actionable alterations identified across tumor types. Methods: The CCCP can detect alterations in 467 tumor-specific genes and exons. The results are categorized into 4 tiers: tier 1 variants are actionable alterations associated with tumor type and tier 2 variants are alterations in targeted pathways, actionable alterations in other tumor types, or alterations in well-established cancer genes. Tier 3 and 4 variants do not currently have potential to be targeted. We retrospectively reviewed 219 consecutive adult oncology patients who underwent CCCP testing between 07/10/2014 and 12/15/2015. We examined clinical charac...